Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670569 | 1.00 | NTRK1 (0.58) | NTRK1CCNT1CDK9CCNCCDK8 | |
| SCHEMBL27717397 | 0.87 | NTRK1 (0.48) | NTRK1CCNT1CDK9CCNCCDK8 | |
| SCHEMBL14670400 | 0.86 | NTRK1 (0.45) | NTRK1CCNT1CDK9CCNCCDK8 | |
| SCHEMBL14670673 | 0.86 | NTRK1 (0.45) | NTRK1CCNT1CDK9CCNCCDK8 | |
| SCHEMBL14670573 | 0.86 | EGFR (0.46) | NTRK1CCNCCDK8EGFRLMNA | |
| SCHEMBL14662047 | 0.86 | EGFR (0.46) | NTRK1CCNCCDK8EGFRLMNA | |
| SCHEMBL14662045 | 0.86 | EGFR (0.46) | NTRK1CCNCCDK8EGFRLMNA | |
| SCHEMBL14670408 | 0.85 | NTRK1 (0.44) | NTRK1CCNT1CDK9CDK2MAP4K1 | |
| SCHEMBL14670525 | 0.85 | NTRK1 (0.44) | NTRK1CCNT1CDK9CDK2MAP4K1 | |
| SCHEMBL14670669 | 0.82 | NTRK1 (0.42) | NTRK1STK17BSTK17AMAP4K1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | ASTRAZENECA (SE) | 2008-08-14 | — | — | US | disclosed |
| CN-101218229-A | Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | CN | disclosed |
| EP-1888561-A1 | PYRAZOLYL-AMINO- SUBSTITUTED PYRIMIDINES AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006117560-A1 | PYRAZOLYL-AMINO- SUBSTITUTED PYRIMIDINES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | TYMS, TYMP, DPYD | NTRK1 4196/4885CCNT1 124/4885CDK9 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.